Iovance Biotherapeutics, Inc. (0JDK.L)

USD 3.3

(2.48%)

Revenue Summary of Iovance Biotherapeutics, Inc.

  • Iovance Biotherapeutics, Inc.'s latest annual revenue in 2023 was 1.18 Million USD , down 0.0% from previous year.
  • Iovance Biotherapeutics, Inc.'s latest quarterly revenue in 2024 Q2 was 31.1 Million USD , up 4250.49% from previous quarter.
  • Iovance Biotherapeutics, Inc. reported a annual revenue of - USD in annual revenue 2022, down 0.0% from previous year.
  • Iovance Biotherapeutics, Inc. reported a annual revenue of - USD in annual revenue 2021, down 0.0% from previous year.
  • Iovance Biotherapeutics, Inc. reported a quarterly revenue of 31.1 Million USD for 2024 Q2, up 4250.49% from previous quarter.
  • Iovance Biotherapeutics, Inc. reported a quarterly revenue of 238 Thousand USD for 2023 Q2, down 0.0% from previous quarter.

Annual Revenue Chart of Iovance Biotherapeutics, Inc. (2023 - 2012)

Historical Annual Revenue of Iovance Biotherapeutics, Inc. (2023 - 2012)

Year Revenue Revenue Growth
2023 1.18 Million USD 0.0%
2022 - USD 0.0%
2021 - USD 0.0%
2020 - USD 0.0%
2019 - USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%
2014 - USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%

Peer Revenue Comparison of Iovance Biotherapeutics, Inc.

Name Revenue Revenue Difference
uniQure N.V. 15.84 Million USD 92.495%
Amicus Therapeutics, Inc. 399.35 Million USD 99.702%
Dynavax Technologies Corporation 232.28 Million USD 99.488%
Illumina, Inc. 4.5 Billion USD 99.974%
IQVIA Holdings Inc. 14.98 Billion USD 99.992%
Neurocrine Biosciences, Inc. 1.88 Billion USD 99.937%
Thermo Fisher Scientific Inc. 42.85 Billion USD 99.997%
Biogen Inc. 9.83 Billion USD 99.988%
Agios Pharmaceuticals, Inc. 26.82 Million USD 95.567%
bluebird bio, Inc. 29.49 Million USD 95.969%
Imunon, Inc. - USD -Infinity%
Mettler-Toledo International Inc. 3.78 Billion USD 99.969%
Myriad Genetics, Inc. 678.4 Million USD 99.825%
Sarepta Therapeutics, Inc. 1.24 Billion USD 99.904%
Supernus Pharmaceuticals, Inc. 607.52 Million USD 99.804%
Nektar Therapeutics 90.12 Million USD 98.681%
Cara Therapeutics, Inc. 20.96 Million USD 94.329%
Perrigo Company plc 4.65 Billion USD 99.974%
Atara Biotherapeutics, Inc. 8.57 Million USD 86.131%
Editas Medicine, Inc. 78.12 Million USD 98.478%
Verastem, Inc. - USD -Infinity%
Walgreens Boots Alliance, Inc. 147.65 Billion USD 99.999%
Waters Corporation 2.95 Billion USD 99.96%
Corbus Pharmaceuticals Holdings, Inc. - USD -Infinity%
Heron Therapeutics, Inc. 127.04 Million USD 99.064%
Unity Biotechnology, Inc. - USD -Infinity%
BioMarin Pharmaceutical Inc. 2.41 Billion USD 99.951%
Sangamo Therapeutics, Inc. 176.23 Million USD 99.325%
Evolus, Inc. 202.08 Million USD 99.412%
Adicet Bio, Inc. - USD -Infinity%
Aclaris Therapeutics, Inc. 31.24 Million USD 96.195%
Regeneron Pharmaceuticals, Inc. 13.11 Billion USD 99.991%
Esperion Therapeutics, Inc. 116.33 Million USD 98.978%
FibroGen, Inc. 147.75 Million USD 99.195%
Agilent Technologies, Inc. 6.83 Billion USD 99.983%
OPKO Health, Inc. 863.49 Million USD 99.862%
Homology Medicines, Inc. -6.65 Million USD 117.877%
Geron Corporation 237 Thousand USD -401.688%
Alnylam Pharmaceuticals, Inc. 1.82 Billion USD 99.935%
Exelixis, Inc. 1.83 Billion USD 99.935%
Viking Therapeutics, Inc. - USD -Infinity%
Anavex Life Sciences Corp. - USD -Infinity%
Intellia Therapeutics, Inc. 36.27 Million USD 96.722%
Zoetis Inc. 8.54 Billion USD 99.986%
Axsome Therapeutics, Inc. 270.6 Million USD 99.561%
Abeona Therapeutics Inc. 3.5 Million USD 66.029%
Vertex Pharmaceuticals Incorporated 9.86 Billion USD 99.988%
Kala Pharmaceuticals, Inc. - USD -Infinity%
Ionis Pharmaceuticals, Inc. 787.64 Million USD 99.849%
Corcept Therapeutics Incorporated 482.37 Million USD 99.754%
Halozyme Therapeutics, Inc. 829.25 Million USD 99.857%
Blueprint Medicines Corporation 249.38 Million USD 99.523%
Insmed Incorporated 305.2 Million USD 99.61%
TG Therapeutics, Inc. 233.66 Million USD 99.491%
Incyte Corporation 3.69 Billion USD 99.968%
Emergent BioSolutions Inc. 1.04 Billion USD 99.887%